← All trials
NCT06091436
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 24, 2023
- Primary completion
- Feb 29, 2024
- Completion date
- Aug 31, 2024
- First posted
- Oct 19, 2023
- Last posted
- Oct 19, 2023
- Enrollment
- 176
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GeneScience Pharmaceuticals Co., Ltd.Lead sponsor
- Sun Yat-Sen UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.